Table 3.

Changes in markers of mineral metabolism, inflammatory markers, and kidney function from baseline to 6 months

ParameterCalcitriol, n=57Cholecalciferol, n=58Between-Group P Value
Baseline6 moP ValueBaseline6 moP Value
25(OH)D, ng/ml21.7±7.721.2±7.50.2023.0±7.634.8±9.3<0.001<0.001
1,25(OH)2D, pg/ml29.4±11.230.4±15.10.8429.2±11.128.5±9.70.450.44
Vitamin D binding globulin, μg/ml263±46251±400.04257±48250±480.290.54
Calcium, mg/dl9.0±0.49.1±±0.49.0±0.40.550.48
Phosphorus, mg/dl3.6±0.63.6±0.70.663.6±0.73.7±0.70.420.85
PTH, pg/ml94 (61–139)57 (32–109)<0.00199 (62–146)102 (59–135)0.740.004
FGF23, pg/ml86.0 (56.3–118.2)117.0 (85.5–164.5)<0.00189.0 (60.3–131.8)117.1 (80.9–189.1)<0.0010.26
hs-CRP, mg/dl3.4 (1.5–6.7)3.9 (0.3–2.1)0.303.0 (1.2–7.9)3.1 (1.7–8.3)0.840.69
IL-6, mg/dl3.0 (1.8–4.2)3.1 (1.8–5.1)0.713.5 (1.8–4.7)3.4 (2.0–5.2)0.990.78
GFR, ml/min per 1.73 m232.8±10.031.6±11.00.0433.3±10.431.3±
Urinary albumin-to-creatinine ratio, mg/g255.2 (39.6–844.7)131.4 (21.7–708.6)0.02166.1 (30.3–611.3)355.6 (25.9–830.4)0.350.02
  • Values are expressed as mean±SD or median (interquartile range). Comparisons were performed by using paired t tests (6 months versus baseline) and two-sample t tests (between groups) for all variables except PTH, FGF23, CRP, and IL-6, for which signed rank tests (6 months versus baseline) and rank sum tests (between groups) were performed. 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25 dihydroxyvitamin D; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; hs-CRP, high-sensitivity C-reactive protein.